A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes

Human botulism is primarily caused by botulinum neurotoxin (BoNT) serotypes A, B and E, with around 1% caused by serotype F (BoNT/F). BoNT/F comprises at least seven different subtypes with the amino acid sequence difference between subtypes as high as 36%. The sequence differences present a significant challenge for generating monoclonal antibodies (mAbs) that can bind, detect and neutralize all BoNT/F subtypes. We used repertoire cloning of immune mouse antibody variable (V) regions and yeast display to generate a panel of 33 lead single chain Fv (scFv) mAbs that bound one or more BoNT/F subtypes with a median equilibrium dissociation constant (KD) of 4.06 × 10−9 M. By diversifying the V-regions of the lead mAbs and selecting for cross reactivity we generated five mAbs that bound each of the seven subtypes. Three scFv binding non-overlapping epitopes were converted to IgG that had KD for the different BoNT/F subtypes ranging from 2.2×10−8 M to 1.47×10−12 pM. An equimolar combination of the mAbs was able to potently neutralize BoNT/F1, F2, F4 and F7 in the mouse neutralization assay. The mAbs have potential utility as diagnostics capable of recognizing the known BoNT/F subtypes and could be developed as antitoxins to prevent and treat type F botulism.

[1]  J. Marks,et al.  Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H , 2016, The Journal of infectious diseases.

[2]  Brian H. Raphael,et al.  A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin. , 2016, The Journal of infectious diseases.

[3]  S. Fleishman,et al.  Overcoming a species-specificity barrier in development of an inhibitory antibody targeting a modulator of tumor stroma , 2016, Protein engineering, design & selection : PEDS.

[4]  Leonard A. Smith,et al.  Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B , 2015, Toxins.

[5]  Leonard A. Smith,et al.  Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity , 2015, PloS one.

[6]  J. Zenilman,et al.  Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A , 2014, Antimicrobial Agents and Chemotherapy.

[7]  Xavier Robert,et al.  Deciphering key features in protein structures with the new ENDscript server , 2014, Nucleic Acids Res..

[8]  S. Arnon,et al.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. , 2014, The Journal of infectious diseases.

[9]  B. Dasgupta,et al.  Botulinum and Tetanus Neurotoxins: Neurotransmission And Biomedical Aspects , 2013 .

[10]  J. Marks,et al.  Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. , 2012, Analytical biochemistry.

[11]  J. Marks,et al.  Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. , 2012, Analytical biochemistry.

[12]  R. Fagan,et al.  Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Leonard A. Smith,et al.  Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. , 2011, Protein engineering, design & selection : PEDS.

[14]  Leonard A. Smith,et al.  Extraction of BoNT/A, /B, /E, and /F with a Single, High Affinity Monoclonal Antibody for Detection of Botulinum Neurotoxin by Endopep-MS , 2010, PloS one.

[15]  Brian H. Raphael,et al.  Sequence Diversity of Genes Encoding Botulinum Neurotoxin Type F , 2010, Applied and Environmental Microbiology.

[16]  R. Stevens,et al.  A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. , 2010, Journal of molecular biology.

[17]  I. Scheibel,et al.  Preliminary report on the isolation of an apparently new type of CI. botulinum. , 2009, Acta pathologica et microbiologica Scandinavica.

[18]  S. Arnon.  Creation and Development of the Public Service Orphan Drug Human Botulism Immune Globulin , 2007, Pediatrics.

[19]  L. O. Ticknor,et al.  Genetic Diversity among Botulinum Neurotoxin-Producing Clostridial Strains , 2006, Journal of bacteriology.

[20]  N. Jewell,et al.  Human botulism immune globulin for the treatment of infant botulism. , 2006, The New England journal of medicine.

[21]  Leonard A. Smith,et al.  Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization , 2005, Infection and Immunity.

[22]  R. Siegel,et al.  Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. , 2005, Journal of molecular biology.

[23]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[24]  Leonard A. Smith,et al.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[26]  R. Stevens,et al.  Sequence homology and structural analysis of the clostridial neurotoxins. , 1999, Journal of molecular biology.

[27]  A. Corwin,et al.  Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  F. Corpet.  Multiple sequence alignment with hierarchical clustering. , 1988, Nucleic acids research.

[29]  D. Gill,et al.  Bacterial toxins: a table of lethal amounts , 1982, Microbiological reviews.

[30]  R. Black,et al.  Hypersensitivity reactions associated with botulinal antitoxin. , 1980, The American journal of medicine.

[31]  K. Hill,et al.  Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. , 2013, Current topics in microbiology and immunology.

[32]  R. Stevens,et al.  Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin , 2007, Nature Biotechnology.

[33]  S. Arnon.  Clinical Trial of Human Botulism Immune Globulin , 1993 .

[34]  M. Hanes,et al.  Efficacy of Prophylactic and Therapeutic Administration of Antitoxin for Inhalation Botulism , 1993 .

[35]  G. S. Burke.  The Occurrence of Bacillus botulinus in Nature. , 1919, Journal of bacteriology.